2nd Jun 2016 06:16
LONDON (Alliance News) - AstraZeneca PLC on Thursday said it has agreed to licence Zurampic to Grunenthal GmbH in Europe and Latin America, a deal that could see the London-listed pharmaceutical firm receive up to USD230.0 million over the life of the contract.
Grunenthal, a German pharmaceutical and research company, will acquire the exclusive rights to Zurampic in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, and in all Latin-American countries including Mexico, the Dominican Republic and Cuba.
Zurampic was approved by the European Medicines Agency in February 2016, in combination with a xanthine oxidase inhibitor, for the adjunctive treatment of hyperuricemia, which is excess of uric acid in the blood, in adult patients with uncontrolled gout.
Grunenthal also will obtain the exclusive rights to the fixed-dose combination of lesinurad and allopurinol in those markets, AstraZeneca said.
AstraZeneca will manufacture Zurampic and will receive up to USD230.0 million over the lifetime of the deal. Grunenthal also will pay tiered, low double-digit royalties on annual product sales.
Grunenthal has the option to manufacture Zurampic from the start of October 2021.
By Joshua Warner; [email protected]; @JoshAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca